Affiliation: Royal Marsden Hospital
- An elective single autograft with high-dose melphalan: single-center study of 451 patientsB Sirohi
Leukaemia and Myeloma Units, Royal Marsden Hospital and Institute of Cancer Research, Sutton, Surrey, UK
Bone Marrow Transplant 36:19-24. 2005..009). EFS was also longer if beta-2-microglobulin was <3.5 mg/l (P=0.0056) and patients were <60 years of age (P=0.033). We conclude that with a single planned autograft, patients with myeloma have an excellent outcome...
- The implication of compromised renal function at presentation in myeloma: similar outcome in patients who receive high-dose therapy: a single-center study of 251 previously untreated patientsB Sirohi
Leukaemia and Myeloma Units, Royal Marsden NHS Trust, Sutton, Surrey, United Kingdom
Med Oncol 18:39-50. 2001..7, PS > or = 2, and light-chain myeloma were predictive of shorter EFS. The study shows that with modern intensive schedules of treatment, renal disease at presentation in isolation does not compromise outcome...
- Haploidentical vs autologous hematopoietic stem cell transplantation in patients with acute leukemia beyond first remissionS Singhal
Royal Marsden Hospital, Surrey, UK
Bone Marrow Transplant 31:889-95. 2003..If an autograft is not feasible because of nonavailability of autologous cells or very advanced disease, PMRDT is a potential alternative...
- Glomerular filtration rate prior to high-dose melphalan 200 mg/m(2) as a surrogate marker of outcome in patients with myelomaB Sirohi
Leukaemia Unit, Royal Marsden NHS Trust, Surrey, UK
Br J Cancer 85:325-32. 2001....
- Thalidomide after allogeneic haematopoietic stem cell transplantation: activity in chronic but not in acute graft-versus-host diseaseS Kulkarni
Leukaemia and Myeloma Units, The Royal Marsden Hospital, Downs Road, Sutton, Surrey SM2 5PT, UK
Bone Marrow Transplant 32:165-70. 2003..The principal causes of death were progressive chronic GVHD (n=29) and relapsed leukaemia (n=7). In conclusion, thalidomide has no activity in acute GVHD, but has some activity in chronic GVHD in combination with other agents...
- Comparison of new patients with Bence-Jones, IgG and IgA myeloma receiving sequential therapy: the need to regard these immunologic subtypes as separate disease entities with specific prognostic criteriaB Sirohi
Leukaemia and Myeloma Units, Royal Marsden NHS Trust, Sutton, Surrey, UK
Bone Marrow Transplant 28:29-37. 2001....
- Impact of cytogenetics on the outcome of autotransplantation for acute myeloid leukemia in first remission: is the benefit of intensive pretransplant therapy limited to patients with good karyotypes?J Mehta
The Royal Marsden Hospital and the Institute for Cancer Research, Downs Road, Sutton, Surrey SM2 5PT, UK
Bone Marrow Transplant 32:157-64. 2003..In them, it may be worthwhile exploring alternatives not normally used in AML (eg high-dose cyclophosphamide) that could have antileukemic effects while permitting mobilization of stem cells...
- Allogeneic blood and bone-marrow stem-cell transplantation in haematological malignant diseases: a randomised trialR Powles
Leukaemia Unit, Royal Marsden Hospital, and Institute of Cancer Research, Sutton, Surrey, UK
Lancet 355:1231-7. 2000..Autologous transplantation with peripheral blood stem cells (PBSC) results in faster haematopoietic-cell repopulation than with bone marrow. We prospectively compared bone marrow and PBSC for allogeneic transplantation...
- High-dose melphalan and autotransplantation followed by post transplant maintenance chemotherapy for acute lymphoblastic leukemia in first remissionJ Mehta
Leukaemia Unit, The Royal Marsden Hospital, Surrey, UK
Bone Marrow Transplant 33:1107-14. 2004..These data show that a high-dose melphalan-based autograft is safe and could be widely applicable in ALL in first remission, and that maintenance chemotherapy very likely contributes to improved outcome of autografted ALL patients...
- Collection of peripheral blood stem cells in newly diagnosed myeloma patients without any prior cytoreductive therapy: the first step towards an 'operational cure'?R Powles
Leukaemia and Myeloma Units, Royal Marsden Hospital and Institute of Cancer Research, Sutton, UK
Bone Marrow Transplant 30:479-84. 2002..We conclude that it is possible to harvest stem cells in three-quarters of untreated myeloma patients. Increasing the number of apheresis procedures is needed to improve the number of CD34(+) cells collected...
- The role of maintenance chemotherapy after autotransplantation for acute lymphoblastic leukemia in first remission: single-center experience of 100 patientsB Sirohi
Leukaemia Unit, The Royal Marsden Hospital, Surrey, UK
Bone Marrow Transplant 42:105-12. 2008..0001). Maintenance chemotherapy intensity was an independent determinant of outcome in Cox analysis. Maintenance chemotherapy after autotransplantation reduces relapse and improves outcome in adult patients with ALL...
- Response to induction chemotherapy is not essential to obtain survival benefit from high-dose melphalan and autotransplantation in myelomaS Singhal
Myeloma Unit, The Royal Marsden Hospital, Surrey, UK
Bone Marrow Transplant 30:673-9. 2002..Myeloma patients should not be disqualified from an autograft based upon lack of response to induction chemotherapy...
- Long-term outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin's lymphomaB Sirohi
Lymphoma Unit, Royal Marsden Hospital and Institute of Cancer Research, Sutton, Surrey, UK
Ann Oncol 19:1312-9. 2008..The purpose of this study was to assess prognostic factors and outcome of patients with relapsed/refractory Hodgkin's lymphoma (HL) who received high-dose chemotherapy and autologous stem-cell transplant (ASCT)...
- Use of physiological doses of human growth hormone in haematological patients receiving intensive chemotherapy promotes haematopoietic recovery: a double-blind randomized, placebo-controlled studyB Sirohi
Haemato Oncology Unit, Royal Marsden Hospital and Institute of Cancer Research, Sutton, Surrey, UK
Bone Marrow Transplant 39:115-20. 2007..The study drug was well tolerated. Treatment with hGH in physiological doses improves platelet recovery, but is not associated with a lower relapse rate or improved anthropometric parameters in patients receiving intensive chemotherapy...
- Does donor-recipient ABO incompatibility protect against relapse after allogeneic bone marrow transplantation in first remission acute myeloid leukemia?J Mehta
Leukaemia Unit, The Royal Marsden Hospital Institute for Cancer Research, Surrey, UK
Bone Marrow Transplant 29:853-9. 2002..We conclude that ABO incompatibility may influence relapse rates and survival favorably after allogeneic BMT. It is not known if this holds true for allogeneic blood stem cell transplants...
- An open, randomized, controlled, phase II, single centre, two-period cross-over study to compare the quality of life and toxicity experienced on PEG interferon with interferon-alpha2b in patients with multiple myeloma maintained on a steady dose of interfB Sirohi
Leukaemia and Myeloma Units, Royal Marsden NHS Trust, Surrey SM2 5PT and Clinical Trials and Statistics Unit, Institute of Cancer Research, UK
Ann Oncol 18:1388-94. 2007..To compare the effects of pegylated interferon-alpha2b (P-IFN) and interferon-alpha2b (IFN) on quality of life (QoL) and toxicity in patients with multiple myeloma maintained on a steady dose of IFN...
- Allogeneic transplantation from HLA-matched sibling or partially HLA-mismatched related donors for primary refractory acute leukemiaS Singhal
Royal Marsden Hospital, Surrey, UK
Bone Marrow Transplant 29:291-5. 2002....
- A study to determine the safety profile and maximum tolerated dose of micafungin (FK463) in patients undergoing haematopoietic stem cell transplantationB Sirohi
Leukaemia and Myeloma Unit, Royal Marsden Hospital, Sutton, Surrey, UK
Bone Marrow Transplant 38:47-51. 2006..Criteria for MTD were not met; no patient had a Grade 3 or 4 adverse event considered causally related to micafungin. Thus, the MTD of micafungin can be inferred to be 8 mg/kg/day or higher...
- Two different first-line 5-fluorouracil regimens with or without oxaliplatin in patients with metastatic colorectal cancerD Cunningham
Department of Medicine, Royal Marsden Hospital, London and Surrey, UK
Ann Oncol 20:244-50. 2009..The aim of this multicentre, open-label, phase IIIb study was to assess the addition of oxaliplatin to two different 5-FU regimens...
- The management of poor-prognosis, non-seminomatous germ-cell tumoursB Sirohi
The Academic Unit of Radiotherapy and Oncology, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Sutton, Surrey, UK
Clin Oncol (R Coll Radiol) 17:543-52. 2005..To advance the management of this disease, physicians treating poor-prognosis disease are urged to support multi-centre trials, such as the recently launched MRC TE23 study comparing BEP and CBOP/BEP...
- The prognostic role of WHO classification, urinary 5-hydroxyindoleacetic acid and liver function tests in metastatic neuroendocrine carcinomas of the gastroenteropancreatic tractV Formica
Department of Medicine, Royal Marsden Hospital, London and Sutton, Surrey, UK
Br J Cancer 96:1178-82. 2007....
- Reassessing autotransplantation for acute myeloid leukaemia in first remission - a matched pair analysis of autologous marrow vs peripheral blood stem cellsB Sirohi
Royal Marsden Hospital and Institute of Cancer Research Surrey, UK
Bone Marrow Transplant 33:1209-14. 2004..Autografting should be reassessed in a randomised trial for first remission AML patients using peripheral blood as a source of stem cells rather than bone marrow...
- Some early phase II trials in previously untreated multiple myeloma: The Royal Marsden experienceB Sirohi
Royal Marsden NHS Trust, Surrey, United Kingdom
Semin Hematol 38:209-18. 2001..Each of these components has shown benefits in selected studies and together they have dramatically improved the outlook for patients with myeloma...
- Consensus conference on European preparedness for haematological and other medical management of mass radiation accidentsN C Gorin
Institut de Radioprotection et de Surete Nucleaire IRSN, Fontenay aux Roses, France
Ann Hematol 85:671-9. 2006
- The impact of donor gender on outcome of allogeneic hematopoietic stem cell transplantation for multiple myeloma: reduced relapse risk in female to male transplantsG Gahrton
Department of Medicine, Karolinska Institute and Karolinska University Hospital, Huddinge, Stockholm, Sweden
Bone Marrow Transplant 35:609-17. 2005..Therefore, a female donor is as good as a male one for male patients, while for female patients gender disparity is a negative factor for outcome...
- The evolving background for high-dose treatment for myelomaB Sirohi
Department of Medical Oncology, Royal Marsden NHS Foundation Trust, London, UK
Bone Marrow Transplant 40:1097-100. 2007....
- Platinum-based chemotherapy in triple-negative breast cancerB Sirohi
Breast Unit, Royal Marsden NHS Foundation Trust, London, UK
Ann Oncol 19:1847-52. 2008..We present our long-term results with platinum-based chemotherapy for TN breast cancer...
- Avascular necrosis of bone--a complication of aggressive therapy for acute lymphoblastic leukemiaS Vaidya
Department of Medical Oncology, Tata Memorial Hospital, Bombay, India
Acta Oncol 37:175-7. 1998..Awareness of this complication is important in order to have an early diagnosis so as to limit disability...